Todos Medical (OTCMKTS:TOMDF – Get Free Report) and PolyPid (NASDAQ:PYPD – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.
Earnings and Valuation
This table compares Todos Medical and PolyPid”s gross revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Todos Medical | $12.23 million | 0.02 | -$43.31 million | N/A | N/A |
PolyPid | N/A | N/A | -$23.86 million | ($12.64) | -0.26 |
PolyPid has lower revenue, but higher earnings than Todos Medical.
Volatility & Risk
Insider and Institutional Ownership
26.5% of PolyPid shares are held by institutional investors. 24.7% of PolyPid shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Todos Medical and PolyPid’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Todos Medical | N/A | N/A | N/A |
PolyPid | N/A | -969.85% | -121.65% |
Analyst Recommendations
This is a breakdown of recent recommendations for Todos Medical and PolyPid, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Todos Medical | 0 | 0 | 0 | 0 | N/A |
PolyPid | 0 | 0 | 1 | 0 | 3.00 |
PolyPid has a consensus target price of $14.00, suggesting a potential upside of 324.24%. Given PolyPid’s higher possible upside, analysts clearly believe PolyPid is more favorable than Todos Medical.
Summary
PolyPid beats Todos Medical on 6 of the 9 factors compared between the two stocks.
About Todos Medical
Todos Medical Ltd., a vitro diagnostics company, develops and commercializes blood tests for the detection of cancer and Alzheimer disease in the United States. The company develops Total Biochemical Infrared Analysis, a proprietary cancer-screening technology using peripheral blood spectroscopy analysis for examination into cancer's influence on the immune system; Lymphocyte Proliferation Test, a diagnostic blood test that determines the ability of peripheral blood lymphocytes and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle; and blood tests for the detection of neurodegenerative disorders, such as Alzheimer's disease. Its cancer screening and diagnosis products include TM-B1 and TM-B2 for breast cancer tests; and TMC blood test for the screening and diagnosis of colon cancer. The company also offers Tollovid, a 3CL protease inhibitor dietary supplement to support healthy immune function against circulating coronaviruses; and Tollovir, an antiviral treatment for Covid-19 that is in Phase 2 clinical trial. Todos Medical Ltd. has a collaboration agreement with Integrated Health LLC, as well as has agreements with various companies to develop screening tests for SARS-nCoV-2; and to distribute certain COVID-19 test kits. Todos Medical Ltd. was incorporated in 2010 and is headquartered in Tel Aviv, Israel.
About PolyPid
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Receive News & Ratings for Todos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Todos Medical and related companies with MarketBeat.com's FREE daily email newsletter.